Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%

Cutis

Volumn 75, Issue 5, 2005, Pages 289-293

  Dosik, Jonathan S ^a,b   Homer, Kenneth ^a   Arsonnaud, Stéphanie ^b  

^a TKL RESEARCH INC   (United States)

^b Galderma R and D Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; TAZAROTENE;

ACNE; ADULT; AGED; ARTICLE; BACK; CLINICAL ARTICLE; CREAM; EPIDERMIS; ERYTHEMA; FEMALE; GEL; HUMAN; MALE; PROTECTIVE CLOTHING; SKIN IRRITATION; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE;

ACNE VULGARIS; ADULT; AGED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; NICOTINIC ACIDS; OINTMENTS; RETINOIDS; SKIN IRRITANCY TESTS;

EID: 20444441044     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Leyden JL. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(suppl 3):S200-S210.
2. Kim BH, Lee YS, Kang KS. The mechanism of retinol-induced irritation and its application to anti-irritant development. Toxicol Lett. 2003;146:65-73.
3. Verschoore M, Langner A, Wolska H, et al. Vehicle controlled study of CD 271 lotion in the topical treatment of acne vulgaris. J Invest Dermatol. 1993;100:221A.
4. Verschoore M, Langner A, Wolska H, et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol. 1991;124:368-371.
5. Bernard BA. Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol. 1993;6(suppl 1):61-69.
6. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49(suppl 3):S227-S232.
7. Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis. 2003;72:76-81.
8. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol. 2003;4:197-202.
9. Berger RS, Bowman JP. A reappraisal of the 21-day cumulative irritation test in man. J Toxicol Cutan Ocul Toxicol. 1982;1:109-115.
10. Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in General Medicine. Vol 1. 4th ed. New York, NY: McGraw-Hill; 1993:1689-1716.